- Home
- AKRO vs MGNI Comparison
AKRO vs MGNI Comparison
Compare AKRO & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- MGNI
- Stock Information
- Founded
- AKRO 2017
- MGNI 2007
- Country
- AKRO United States
- MGNI United States
- Employees
- AKRO N/A
- MGNI N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- MGNI Computer Software: Programming Data Processing
- Sector
- AKRO Health Care
- MGNI Technology
- Exchange
- AKRO Nasdaq
- MGNI Nasdaq
- Market Cap
- AKRO 3.7B
- MGNI 3.1B
- IPO Year
- AKRO 2019
- MGNI N/A
- Fundamental
- Price
- AKRO $46.50
- MGNI $19.17
- Analyst Decision
- AKRO Strong Buy
- MGNI Strong Buy
- Analyst Count
- AKRO 8
- MGNI 11
- Target Price
- AKRO $80.38
- MGNI $26.18
- AVG Volume (30 Days)
- AKRO 1.2M
- MGNI 3.1M
- Earning Date
- AKRO 11-07-2025
- MGNI 11-05-2025
- Dividend Yield
- AKRO N/A
- MGNI N/A
- EPS Growth
- AKRO N/A
- MGNI N/A
- EPS
- AKRO N/A
- MGNI 0.29
- Revenue
- AKRO N/A
- MGNI $685,074,000.00
- Revenue This Year
- AKRO N/A
- MGNI $2.09
- Revenue Next Year
- AKRO N/A
- MGNI $11.41
- P/E Ratio
- AKRO N/A
- MGNI $66.93
- Revenue Growth
- AKRO N/A
- MGNI 5.52
- 52 Week Low
- AKRO $21.34
- MGNI $8.22
- 52 Week High
- AKRO $58.40
- MGNI $26.65
- Technical
- Relative Strength Index (RSI)
- AKRO 47.87
- MGNI 30.70
- Support Level
- AKRO $45.20
- MGNI $18.35
- Resistance Level
- AKRO $47.40
- MGNI $20.79
- Average True Range (ATR)
- AKRO 1.46
- MGNI 1.16
- MACD
- AKRO 0.06
- MGNI -0.48
- Stochastic Oscillator
- AKRO 34.90
- MGNI 8.42
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About MGNI Magnite Inc.
Magnite Inc is one of the supply-side platform providers, or SSP, in online advertising. The firm generate its revenue from the programmatic sale of CTV ad inventory, from mobile online sites and apps, and the remaining from websites accessed via computer.